What did the ASPIRE and ENDEAVOR trials show?

ASPIRE showed adding carfilzomib to lenalidomide-dexamethasone extended progression-free survival to about 26 months; ENDEAVOR showed carfilzomib-dexamethasone roughly doubled progression-free survival versus bortezomib-dexamethasone.

What is the main safety concern with carfilzomib?

Cardiovascular toxicity, including heart failure, high blood pressure, and cardiomyopathy, along with infusion reactions and low blood counts. Patients need cardiac risk assessment and monitoring during treatment.

Is carfilzomib something I can use as a research peptide?

No. Although it is technically a tetrapeptide epoxyketone, it is a hospital-administered chemotherapy with serious cardiac risks, given only under oncology supervision, and is not a self-use research peptide.

EMA-approvedaka Kyprolis

Carfilzomib — Complete Research Guide (2026)

Q: How does carfilzomib work?

It irreversibly blocks the proteasome, the cell's protein-recycling machinery. Myeloma cells depend heavily on the proteasome, so blocking it causes toxic protein build-up and cell death.

Last updated 2026-06-30

TL;DR

Carfilzomib (also known as Kyprolis) is a peptide catalogued under Therapeutic Peptides (Proteasome inhibitor (tetrapeptide)). It is described as: 20S proteasome. Documented context: Multiple myeloma. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Carfilzomib?

Carfilzomib (Kyprolis) is a tetrapeptide epoxyketone proteasome inhibitor approved for relapsed or refractory multiple myeloma, initially via FDA accelerated approval in 2012 and later in combination regimens supported by the pivotal ASPIRE and ENDEAVOR phase 3 trials.

Evidence is high-level and clinical, from large randomized trials with progression-free and overall survival endpoints.

It is a regulator-approved intravenous oncology drug, not an investigational or wellness peptide.

How does Carfilzomib work?

Carfilzomib irreversibly binds and inhibits the chymotrypsin-like activity of the 20S proteasome, blocking degradation of ubiquitinated proteins.

The resulting accumulation of misfolded proteins overwhelms myeloma cells, which are highly dependent on proteasome function, triggering endoplasmic-reticulum stress and apoptosis.

What does the research say about Carfilzomib?

In the ASPIRE trial, adding carfilzomib to lenalidomide-dexamethasone improved median progression-free survival to 26.3 versus 17.6 months in relapsed multiple myeloma. ^[1]
In the ENDEAVOR trial, carfilzomib-dexamethasone roughly doubled median progression-free survival versus bortezomib-dexamethasone (18.7 vs 9.4 months). ^[2]
The ARROW trial showed once-weekly carfilzomib (70 mg/m2) improved progression-free survival over the twice-weekly 27 mg/m2 schedule with a comparable safety profile. ^[3]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma — Stewart AK et al., The New England Journal of Medicine 2015. (Randomized phase 3 trial (ASPIRE))
[2] Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study — Dimopoulos MA et al., The Lancet Oncology 2016. (Randomized phase 3 trial (ENDEAVOR))
[3] Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study — Moreau P et al., The Lancet Oncology 2018. (Randomized phase 3 trial (ARROW))
[4] Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis — Shah C et al., Leukemia and Lymphoma 2018. (Systematic review and meta-analysis)
[5] Incidence and Management of Carfilzomib-induced Cardiovascular Toxicity; A Systematic Review and Meta-analysis — Latif A et al., Cardiovascular and Hematological Disorders Drug Targets 2021. (Systematic review and meta-analysis)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

Carfilzomib is a physician-administered intravenous drug given on protocol-defined weekly or twice-weekly schedules, usually combined with dexamethasone with or without lenalidomide or daratumumab.

This is context only, not clinical guidance; the treating haemato-oncology team sets dose, schedule, hydration, and cardiac monitoring.

Side effects & safety profile

Carfilzomib carries notable cardiovascular toxicity: heart failure, hypertension, cardiomyopathy, and ischaemic events, quantified in systematic reviews and meta-analyses of the trials.

Acute infusion reactions, dyspnoea, thrombocytopenia, anaemia, and renal impairment also occur, and rare thrombotic microangiopathy is reported.

Cardiac risk assessment, blood-pressure control, and hydration are important, and clinicians weigh these risks against the drug's efficacy in relapsed disease.

Stacking & combinations

Carfilzomib is used within combination myeloma regimens, most established with dexamethasone alone (Kd) or with lenalidomide and dexamethasone (KRd).

Finding Carfilzomib vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

It is an intravenous proteasome inhibitor approved for relapsed or refractory multiple myeloma, typically given in combination with dexamethasone with or without lenalidomide.

References

[1] Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma — Stewart AK et al., The New England Journal of Medicine 2015. PMID: 25482145. View sourceStudy: Randomized phase 3 trial (ASPIRE)Adding carfilzomib to lenalidomide-dexamethasone significantly prolonged progression-free survival (26.3 vs 17.6 months) in relapsed multiple myeloma.
[2] Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study — Dimopoulos MA et al., The Lancet Oncology 2016. PMID: 26671818. View sourceStudy: Randomized phase 3 trial (ENDEAVOR)Carfilzomib-dexamethasone doubled median progression-free survival versus bortezomib-dexamethasone (18.7 vs 9.4 months).
[3] Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study — Moreau P et al., The Lancet Oncology 2018. PMID: 29866475. View sourceStudy: Randomized phase 3 trial (ARROW)Once-weekly carfilzomib 70 mg/m2 improved progression-free survival over the twice-weekly 27 mg/m2 schedule with comparable safety.
[4] Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis — Shah C et al., Leukemia and Lymphoma 2018. PMID: 29465266. View sourceStudy: Systematic review and meta-analysisPooled trial data confirm a clinically meaningful incidence of cardiovascular adverse events, including heart failure and hypertension, with carfilzomib.
[5] Incidence and Management of Carfilzomib-induced Cardiovascular Toxicity; A Systematic Review and Meta-analysis — Latif A et al., Cardiovascular and Hematological Disorders Drug Targets 2021. PMID: 33845729. View sourceStudy: Systematic review and meta-analysisQuantifies the incidence of carfilzomib cardiovascular toxicity and reviews monitoring and management strategies to mitigate it.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.